REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Dane Leone - Raymond James Alec Stranahan - Bank of America Lisa Walter - RBC Capital Markets Brian Skorney - Baird Mani Foroohar - Leerink Partners Operator Good day, and thank you for standing by. W ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (S ...

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Dane Leone - RJF Alec Stranahan - Bank of America Ellie Merle - UBS Lisa Walter - RBC Andreas Argyrides - Wedbush Securities Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by. W ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ET Company Participants Patrick Christmas - EVP and Chief Legal Officer Ken Mills - CEO Steve Pakola - Chief Medical Officer Vit Vasista - CFO Conference Call Participants Gena Wang - Barclays Dane Leone - Raymond James Gospel Enyindah-Asonye - Morgan Stanley Alec Stranahan - Bank of America Ellie Merle - UBS Lisa Walter - RBC Capital Markets Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for st ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Dane Leone - Raymond James Lisa Walter - RBC Capital Markets Andreas Argyrides - Wedbush Securities Caroline Palomeque - Berenberg Operator Hello, and thank you for standing by. Welcome to the Q4 and Full Year 2022 REGEN ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37553 REGENXBIO Inc. (Exact name of registrant as specified in its charter) Delaware 47-1851754 (State or other ju ...

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Patrick Christmas - Chief Legal Officer Vit Vasista - Chief Financial Officer Ken Mills - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Lejla Vajzovic - Associate Professor, Ophthalmology; and Director, Duke Vitreoretinal Fellowship Program and Lead Investigator Peter Kaiser - Director, Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic. Confe ...

REGENXBIO Inc. (NASDAQ:RGNX) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Vit Vasista - Chief Financial Officer Ken Mills - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Ellie Merle - UBS Lisa Walter - RBC Capital Markets Andreas Argyrides - Wedbush Securities Mani Foroohar - SVB Securities Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Second Quarter 2022 ...